RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > FDA and Personalized Medicine

FDA and Personalized Medicine

Posted 01 March 2011

Regulatory Focus recently interviewed three US Food and Drug Administration (FDA) officials about the agency's perspective on personalized medicine. Following are excerpts from the interview with Lawrence J. Lesko, PhD, director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research (CDER); Elizabeth Mansfield, PhD, director for personalized medicine, Center for Devices and Radiological Health (CDRH); and Vicki Seyfert-Margolis, PhD, senior advisor for science innovation and policy, Office of the Commissioner.


© 2022 Regulatory Affairs Professionals Society.